Literature DB >> 32376872

Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Cristan A Farmer1, Jessica R Gilbert1, Ruin Moaddel2, Jomy George3, Lilian Adeojo3, Jacqueline Lovett2, Allison C Nugent1,4, Bashkim Kadriu1, Peixiong Yuan1, Todd D Gould5,6, Lawrence T Park1, Carlos A Zarate7.   

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Entities:  

Year:  2020        PMID: 32376872     DOI: 10.1038/s41386-020-0699-7

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  1 in total

1.  (2R,6R)-Hydroxynorketamine (HNK) plasma level predicts poor antidepressant response: is this the end of the HNK pipeline?

Authors:  Chadi G Abdallah
Journal:  Neuropsychopharmacology       Date:  2020-04-14       Impact factor: 7.853

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.